Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Valneva Se ADR (NQ: VALN )

7.060 -0.030 (-0.42%)
Streaming Delayed Price Updated: 9:44 AM EDT, Jun 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,447
Open 6.990
Bid (Size) 7.000 (1)
Ask (Size) 7.690 (3)
Prev. Close 7.090
Today's Range 6.990 - 7.250
52wk Range 6.580 - 17.05
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What Analysts Are Saying About Valneva Stock
Via Benzinga
Valneva Seeks Expanded Use For Its Chikungunya Vaccine In Adolescents With Encouraging Phase 3 Data
Valneva released positive Phase 3 data for its single-shot chikungunya virus vaccine in adolescents. The vaccine is also expected to be approved for use in Brazil. 
Via Benzinga

Performance

YTD
-31.05%
-31.05%
1 Month
-20.14%
-20.14%
3 Month
-8.59%
-8.59%
6 Month
-31.79%
-31.79%
1 Year
-58.41%
-58.41%

More News

Read More
VALN Stock Earnings: Valneva Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Cracking The Code: Understanding Analyst Reviews For Valneva
Via Benzinga
What Analysts Are Saying About Valneva Stock
Via Benzinga
VALN Stock Earnings: Valneva Misses Revenue for Q4 2023
Via InvestorPlace
National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
Expert Ratings for Valneva
Via Benzinga
Smith & Wesson Brands Reports Upbeat Earnings, Joins America's Car-Mart, HCI Group And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Novavax’s dispute resolution and upcoming earnings call
Via MarketBeat
Topics Earnings
Exposures COVID-19 Financial
Chikungunya Vaccine Maker Valneva Secures Non Dilutive Funding To Develop/Expand Its Clinical Pipeline
Via Benzinga
Exposures Product Safety
Analyst Ratings for Valneva
Via Benzinga
Analyst Ratings for Valneva
Via Benzinga
McDonald's, Caterpillar And 3 Stocks To Watch Heading Into Monday
Via Benzinga
Valneva Says Single Chikungunya Vaccine Shows Long-Lasting Antibody Response In Younger, Older Adults
Via Benzinga
FDA Approves World's First Mosquito-Borne Chikungunya Vaccine
Via Benzinga
Exposures Product Safety
Pfizer, Valneva's Tick-Borne Infection Shot: Companies Say 'Positive' Result For Lyme Disease Vaccine Candidate Booster
Via Benzinga
7 Unmatched Stocks: The Untapped Goldmines to Buy Now.
Via InvestorPlace
Why 22nd Century Group Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
AMC Entertainment, Nikola, Cleveland-Cliffs And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Top 5 Health Care Stocks That May Crash This Month
Via Benzinga
Bavarian Nordic Beefs Up Chikungunya Vaccine Race With Valneva With Encouraging Late-Stage Trial Data
Via Benzinga
DICE Therapeutics, Surmodics, Nikola, And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Why Surgalign Holdings Shares Are Trading Lower By Around 75%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.